BOND-003 evaluated the efficacy and safety of cretostimogene grenadenorepvec, an oncolytic immunotherapy, in patients with carcinoma in situ BCG-unresponsive NMIBC.

Obesity in itself is not a contraindication for radical prostatectomy, but it remains a risk factor for poor overall survival.

Imagine it: you’re about to give a speech, have a job interview or undergo a medical procedure. You feel increasingly nervous ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

The UND School of Medicine & Health Sciences conferred the Doctor of Medicine degree on graduating medical students in a commencement ceremony Saturday in Grand Forks. Graduates now will begin a ...

Pathak, M.D. – Associate Professor in the Department of Urology at Mayo Clinic Florida Dr. Pathak’s experience with TULSA-PRO ®, including workflow optimization and clinical outcome data 4:15 – 4:25 p ...

On July 11, 2024, Affluent Medical reached a major milestone with the signature of several agreements with Edwards Lifesciences, a global MedTech player, recognizing the relevance and potential of the ...

Mitchell R. Humphreys, MD, Chair and Professor of the Department of Urology and Director of Bold Forward Unbound at Mayo Clinic Arizona, joined us to discuss. Dr. Humphreys said the goal is to combine ...